Evidence map›Paper›PMID 31076555›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Destabilization of the human RED-SMU1 splicing complex as a basis for host-directed antiinfluenza strategy.

Usama Ashraf, Laura Tengo, Laurent Le Corre, Guillaume Fournier, Patricia Busca, Andrew A McCarthy, Marie-Anne Rameix-Welti, Christine Gravier-Pelletier, Rob W H Ruigrok, Yves Jacob and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Cotranscriptional splicing is required in the cold to produceProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Usama AshrafUnité de Génétique Moléculaire des Virus à ARN, Département de Virologie, Institut Pasteur, 75015 Paris, France.
Laura TengoInstitut de Biologie Structurale (IBS), Université Grenoble-Alpes (UGA), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), CNRS, 38044 Grenoble, France.
Laurent Le CorreLaboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Equipe Synthèse Organique pour la Recherche Biomédicale, Université Paris Descartes, CNRS UMR 8601, 75006 Paris, France.
Guillaume FournierUnité de Génétique Moléculaire des Virus à ARN, Département de Virologie, Institut Pasteur, 75015 Paris, France.
Patricia BuscaLaboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Equipe Synthèse Organique pour la Recherche Biomédicale, Université Paris Descartes, CNRS UMR 8601, 75006 Paris, France.
Andrew A McCarthyEuropean Molecular Biology Laboratory (EMBL) Grenoble, 38042 Grenoble, France.
Marie-Anne Rameix-WeltiUMR1173, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Versailles St. Quentin, 78180 Montigny-le-Bretonneux, France.
Christine Gravier-PelletierLaboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Equipe Synthèse Organique pour la Recherche Biomédicale, Université Paris Descartes, CNRS UMR 8601, 75006 Paris, France.
Rob W H RuigrokInstitut de Biologie Structurale (IBS), Université Grenoble-Alpes (UGA), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), CNRS, 38044 Grenoble, France.
Yves JacobUnité de Génétique Moléculaire des Virus à ARN, Département de Virologie, Institut Pasteur, 75015 Paris, France.ORCID 0000-0001-9125-2374
Pierre-Olivier VidalainUniversité Paris Descartes, CNRS UMR 8601, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Equipe Chimie & Biologie, Modélisation et Immunologie pour la Thérapie, 75006 Paris, France.
Nicolas PietrancostaUniversité Paris Descartes, CNRS UMR 8601, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Equipe Chimie & Biologie, Modélisation et Immunologie pour la Thérapie, 75006 Paris, France nicolas.pietrancosta@sorbonneuniversite.fr thibaut.crepin@ibs.fr nadia.naffakh@pasteur.fr.ORCID 0000-0002-9934-7818
Thibaut CrépinInstitut de Biologie Structurale (IBS), Université Grenoble-Alpes (UGA), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), CNRS, 38044 Grenoble, France; nicolas.pietrancosta@sorbonneuniversite.fr thibaut.crepin@ibs.fr nadia.naffakh@pasteur.fr.
Nadia NaffakhUnité de Génétique Moléculaire des Virus à ARN, Département de Virologie, Institut Pasteur, 75015 Paris, France; nicolas.pietrancosta@sorbonneuniversite.fr thibaut.crepin@ibs.fr nadia.naffakh@pasteur.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New therapeutic strategies targeting influenza are actively sought due to limitations in current drugs available. Host-directed therapy is an emerging concept to target host functions involved in pathogen life cycles and/or pathogenesis, rather than pathogen components themselves. From this perspective, we focused on an essential host partner of influenza viruses, the RED-SMU1 splicing complex. Here, we identified two synthetic molecules targeting an α-helix/groove interface essential for RED-SMU1 complex assembly. We solved the structure of the SMU1 N-terminal domain in complex with RED or bound to one of the molecules identified to disrupt this complex. We show that these compounds inhibiting RED-SMU1 interaction also decrease endogenous RED-SMU1 levels and inhibit viral mRNA splicing and viral multiplication, while preserving cell viability. Overall, our data demonstrate the potential of RED-SMU1 destabilizing molecules as an antiviral therapy that could be active against a wide range of influenza viruses and be less prone to drug resistance.

Indexed as

A549 CellsAntiviral AgentsChromosomal Proteins, Non-HistoneCytokinesHEK293 CellsHost-Pathogen InteractionsHumansMolecular Docking SimulationOrthomyxoviridaeProtein BindingProtein StabilityRNA SplicingRNA Splicing FactorsSpliceosomesAntiviral AgentsChromosomal Proteins, Non-HistoneCytokinesIK protein, humanRNA Splicing FactorsSmu1 protein, humanhost-directed antiviralsinfluenza virusRED-SMU1 splicing complexsplicingstructure-based drug screening

Identifiers

PMID31076555
PMCPMC6561211

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.